Cargando…

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials

INTRODUCTION: Diabetic ketoacidosis (DKA) is traditionally managed using intravenous regular insulin infusion (RII) in intensive care unit (ICU)/high dependency unit (HDU). Subcutaneous fast-acting insulin analogues (FAIAs) may help to manage DKA outside ICU/HDU. Furthermore, combining subcutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Beng Leong, Lee, Wei Feng, Lee, Berlin, Chung, Yan Ee Lynette, Loo, Kee Vooi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923333/ https://www.ncbi.nlm.nih.gov/pubmed/36764729 http://dx.doi.org/10.1136/bmjopen-2022-070131

Ejemplares similares

Diabetic Ketoacidosis Updates: Titratable Insulin Infusions and Long-Acting Insulin Early
por: Kinney, Justin, et al.
Publicado: (2021)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Diabetic Ketoacidosis, Very Severe Hypertriglyceridemia, and Pseudohyponatremia Successfully Managed With Insulin Infusion
por: Ibrahim, Ramzi, et al.
Publicado: (2020)

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
por: Alsofiani, Wafa A, et al.
Publicado: (2022)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
por: Wong, Eva Y., et al.
Publicado: (2021)

PSUN173 Factors determining insulin dose while transitioning from intravenous insulin infusion to subcutaneous insulin in patients with type 2 diabetes following cardiac bypass surgery.
por: Bansal, Beena, et al.
Publicado: (2022)

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
por: Hansen, Bo F., et al.
Publicado: (2012)

Higher-Than-Conventional Subcutaneous Regular Insulin Doses Following Diabetic Ketoacidosis in Children and Adolescents
por: Bağ, Özlem, et al.
Publicado: (2017)

Effect of Continuous Subcutaneous Injection of Insulin Analogues in Pregnant Women with Diabetes Mellitus Complicated with Ketoacidosis
por: Pan, Yunfei, et al.
Publicado: (2021)

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil
por: Laranjeira, Fernanda O, et al.
Publicado: (2016)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

Insulin Requirements for Patients With COVID-19 Presenting With Diabetic Ketoacidosis
por: Nagy, Ahmed, et al.
Publicado: (2023)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
por: King, Allen B., et al.
Publicado: (2016)

Retracted: Effect of Continuous Subcutaneous Injection of Insulin Analogues in Pregnant Women with Diabetes Mellitus Complicated with Ketoacidosis
por: Healthcare Engineering, Journal of
Publicado: (2023)

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
por: Morrow, Linda, et al.
Publicado: (2013)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
por: Melo, Karla F. S., et al.
Publicado: (2019)

ODP231 Outcomes of Weight-based vs. Constant-based Insulin Infusion for Treatment of Diabetic Ketoacidosis in Non-ICU Patients
por: Alrifai, Nada, et al.
Publicado: (2022)

Effect of Bolus Insulin Administration Followed by a Continuous Insulin Infusion on Diabetic Ketoacidosis Management
por: Brown, Hannah D., et al.
Publicado: (2018)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016)

Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis
por: Veroniki, Areti Angeliki, et al.
Publicado: (2022)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

THU326 Subcutaneous Insulin Aspart Every 4 Hours In the Treatment Of COVID-19 Patients With Diabetic Ketoacidosis: A Retrospective Study
por: Chiewchalermsri, Dararat, et al.
Publicado: (2023)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

MON-640 Endogenous Insulin and C-Peptide Suppression Test Using a Rapid-Acting Insulin Analog in the Diagnosis of Insulinoma
por: Laotaveerungrueng, Nattapong, et al.
Publicado: (2020)

PSUN278 Factitious hypoglycemia, diagnostic delay due to insulin assay failure to detect insulin analogues.
por: Harned, Leighton Kahle, et al.
Publicado: (2022)

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
por: Rini, Christopher James, et al.
Publicado: (2015)

Continuous Subcutaneous Insulin Infusion Therapy Resulting in Improved Glycemic Control in Patient With Low Health Literacy
por: Mandal, Shobha, et al.
Publicado: (2021)

FRI654 Concentrated Regular U-500 Insulin In An Automated Insulin Delivery System: A Case Report
por: Aurora, John, et al.
Publicado: (2023)

A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)
por: Klonoff, David C., et al.
Publicado: (2019)

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients
por: Bhurayanontachai, Rungsun, et al.
Publicado: (2018)

Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
por: Kuroda, Akio, et al.
Publicado: (2013)

Efficacy and Safety of Intramuscular Insulin Lispro vs. Continuous Intravenous Regular Insulin for the Treatment of Dogs With Diabetic Ketoacidosis
por: Malerba, Eleonora, et al.
Publicado: (2020)

Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach
por: Faggionato, Edoardo, et al.
Publicado: (2021)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_525nrudg29ujhcqp9hhol3fdh1